"Can you or anyone point to the source of that difference of only one patient resulting in the difference between 0.054 and 0.048? TIA"
Welcome back. The reference is between 5:00 and 8:00 minutes into the presentation. It's an interesting situation. If the FDA is looking for cover to justify approving the drug, this is a rationale that is available. Aside from the will they/ won't they/ should they argument is the investment premise behind the stock. Obviously they are closely related issues, but one can still believe the FDA will probably say "no" and still build an argument that the sp is undervalued. If one believes there is a "yes" decision ahead, then the investment decision makes itself.